Nick Leschly at Endpoints JPM20 (Jeff Rumans)
Bluebird spins itself into two companies, severing gene therapy and cancer units
Bluebird bio, once one of biotech’s flashiest companies, is taking a sweeping step as it looks to right the ship after a series of high …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
